Invivyd (IVVD) EBIT Growth (1y) (2022 - 2025)
Invivyd (IVVD) EBIT Growth (1y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 1,386.07% |
| 10 | Invivyd | 104.14 Mn | -122.55 Mn | 16.07 Mn | 34.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.71% |
| Sep 30, 2025 | 82.31% |
| Jun 30, 2025 | 69.42% |
| Mar 31, 2025 | 63.28% |
| Dec 31, 2024 | 74.95% |
| Sep 30, 2024 | -44.71% |
| Jun 30, 2024 | 8.59% |
| Mar 31, 2024 | -17.96% |
| Dec 31, 2023 | -59.20% |
| Sep 30, 2023 | 9.02% |
| Jun 30, 2023 | -4.11% |
| Mar 31, 2023 | 61.22% |
| Dec 31, 2022 | 41.98% |
| Sep 30, 2022 | 21.66% |
| Jun 30, 2022 | -15.79% |
| Mar 31, 2022 | -160.25% |